Cyclo Therapeutics, Inc.
CYTH
$0.7206
$0.00991.39%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 89.93% | -39.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 89.93% | -39.21% | |||
| Cost of Revenue | -4.69% | 50.00% | |||
| Gross Profit | 109.72% | -45.94% | |||
| SG&A Expenses | 34.07% | -8.42% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 48.00% | 8.42% | |||
| Operating Income | -47.09% | -10.30% | |||
| Income Before Tax | -47.68% | -37.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -47.68% | -37.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -47.68% | -37.72% | |||
| EBIT | -47.09% | -10.30% | |||
| EBITDA | -47.11% | -10.31% | |||
| EPS Basic | -47.20% | -37.52% | |||
| Normalized Basic EPS | -44.72% | -16.90% | |||
| EPS Diluted | -46.43% | -38.25% | |||
| Normalized Diluted EPS | -44.72% | -16.90% | |||
| Average Basic Shares Outstanding | 0.32% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.32% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
